Cargando...
Targeting Solid Tumors With BTK Inhibitors
The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients. Here we review the emerging evidence regarding the clinical potential of BTK inhibitors in solid tumor therapy. The use...
Guardado en:
| Publicado en: | Front Cell Dev Biol |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8079762/ https://ncbi.nlm.nih.gov/pubmed/33937249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2021.650414 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|